Metabolic · Dosing referenceSLU-PP-332 dosage
What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.
- Regulatory status
- Not approved — research use only
- Human amounts
- None established in humans
- Route studied
- —
- Frequency
- Not established
- Half-life
- Unknown in humans
- Evidence grade
- Grade C · Preclinical research
- Vial sizes on the market
- 5 mg · 10 mg · 20 mg
- Other forms seen
- Oral tablets 50 mg (60-count bottle)
What SLU-PP-332 is
SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERR alpha, beta and gamma), not a peptide, studied as an 'exercise mimetic'. In mice it increased oxidative muscle fibres, endurance and energy expenditure and reduced fat mass, and it has been tested in mouse models of heart failure and kidney ageing. No human study has been published and it is not approved for any use; this entry is for research reference only.
Estrogen-related receptors (ERR alpha, beta and gamma) are orphan nuclear receptors that genetic evidence links to skeletal-muscle exercise capacity 1. SLU-PP-332 is a synthetic agonist of all three, with the highest potency for ERR alpha 1. Muscle and whole-body metabolism In a skeletal muscle cell line it increased mitochondrial function and cellular respiration, and in mice it induced an ERR alpha-specific… How it works →
Key evidence
- Billon et al., ACS Chem Biol · 2023 · Cells (skeletal muscle cell line) and animals (mice)
- Billon et al., J Pharmacol Exp Ther · 2024 · Animals (diet-induced obese and ob/ob mice)
- Xu et al., Circulation · 2024 · Animals (mouse pressure-overload heart failure) and cells
What the human evidence shows
No approved or established human dose
We searched PubMed and ClinicalTrials.gov and found no human studies that administered SLU-PP-332. The research described on its page is from cells or animals, and animal amounts do not translate to people.
How long did human studies run?
- No human studies; no duration of human use has been studied 7.
Who was excluded from the studies
- No human population has been studied; no label or contraindications exist 7.
SLU-PP-332 draw calculator
Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.
1 · Vial strength
sizes on the market2 · Water added
3 · Amount per draw
4 · Syringe
Your mix
10 mg + 2 mL water = 5 mg/mL
10 units holds 0.5 mg (500 mcg)
Draw toEnter an amount in step 3
U-100 syringe · 100 units = 1 mL
Computed from your inputs. Not a dose or a recommendation.
Compare water volumes for this vialShow
More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.
| Water | mg/mL | Draw |
|---|---|---|
| 0.5 mL | 20 | — |
| 1 mL | 10 | — |
| 1.5 mL | 6.667 | — |
| 2 mL | 5 | — |
| 2.5 mL | 4 | — |
| 3 mL | 3.333 | — |
| 5 mL | 2 | — |
Supplies and handling
- Lyophilized vialSealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
- Sterile diluentThe diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
- Graduated syringesSized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
- Alcohol prep padsFor wiping vial stoppers before each puncture.
- Nitrile glovesClean gloves for aseptic handling.
- Sharps containerPuncture-resistant container for used needles.
Storage
General research-context handling only: defer to the supplier's documentation for the specific lot; nothing here is a preparation or administration instruction.
- Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
- Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
- Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.
Handling mistakes and troubleshooting
- Added the wrong volume of diluent
- The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
- Shook the vial and it foamed
- Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
- The solution is cloudy or has particles
- Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
- The powder cake looks melted or shrunken before reconstitution
- This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
- Liquid sprayed back when the needle was removed
- Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.
Regulatory status
- Status
- Not approved for any use. No Drugs@FDA application record was returned 8, no registered clinical study was returned by a ClinicalTrials.gov search 7, and SLU-PP-332 does not appear in any category of FDA's May 14, 2026 503A bulk drug substances list 9. A 2026 analytical paper describes it as a drug candidate under investigation as an exercise mimetic with doping potential 6.
- United States (FDA)
- No approved application was identified 8. SLU-PP-332 does not appear in any category of FDA's May 14, 2026 503A bulk drug substances list 9.
- Sport (WADA)
- SLU-PP-332 and estrogen-related receptor agonists are not named on the WADA 2026 Prohibited List 11. Class S0 prohibits at all times any pharmacological substance not addressed elsewhere on the List and with no current approval by any governmental regulatory health authority for human therapeutic use, such as drugs under pre-clinical development 11; SLU-PP-332 has no such approval. A doping-control paper describes it as relevant to sports drug testing 6.
Status varies by country and changes over time. How we describe regulatory status.
SLU-PP-332 compared with related compounds
| Compound | Status | Evidence | Human amounts | Half-life |
|---|---|---|---|---|
| SLU-PP-332 | Not approved — research use only | C | None established | Unknown in humans |
| Tesofensine | Investigational | B | Trial doses | About 234 hours (M1 metabolite about 374 |
| Mazdutide | Approved outside the US | A | Trial doses | 150.9 to 403.5 hours (phase 1b in overwe |
| Cagrilintide | Investigational | A | Trial doses | 159 to 195 hours (phase 1b, co-administe |
| MariTide (maridebart cafraglutide) | Investigational | A | Trial doses | Not reported numerically in the sources |
| Ecnoglutide | Approved outside the US | A | Trial doses | 124 to 138 hours at steady state in heal |
Frequently asked questions
What doses of SLU-PP-332 have been studied in humans?
None that establish an amount. SLU-PP-332 is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.
Is there an established SLU-PP-332 cycle length?
No cycle length or break has been established. Human studies administered SLU-PP-332 for the periods listed on this page; those are study durations, not a recommended course.
How much bacteriostatic water should be added to a SLU-PP-332 vial?
There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.
How many units is a given amount on an insulin syringe?
On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.
What is the half-life of SLU-PP-332?
Unknown in humans
Is SLU-PP-332 FDA-approved?
Not approved — research use only. Not approved for any use. No Drugs@FDA application record was returned 8, no registered clinical study was returned by a ClinicalTrials.gov search 7, and SLU-PP-332 does not appear in any category of FDA's May 14, 2026 503A bulk drug substances list 9. A 2026 analytical paper describes it as a drug candidate under investigation as an exercise mimetic with doping potential 6.
References
- Synthetic ERRalpha/beta/gamma Agonist Induces an ERRalpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity ACS Chem Biol. 2023
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome J Pharmacol Exp Ther. 2024
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function Circulation. 2024
- Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney Am J Pathol. 2023
- Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study Front Physiol. 2025
- In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential Rapid Commun Mass Spectrom. 2026
- ClinicalTrials.gov API search for SLU-PP-332 (no registered studies returned on 23 October 2026) ClinicalTrials.gov. 2026
- Drugs@FDA application data queried through openFDA for SLU-PP-332 (no matching application record returned on 23 October 2026) openFDA / Drugs@FDA. 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (categories 1, 2 and 3; updated May 14, 2026) FDA. 2026
- PubChem compound record for SLU-PP-332 (CID 5338394; CAS 303760-60-3) PubChem. 2026
- International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026
Last reviewed October 23, 2026 by the Amiravo editorial team. Editorial policy · Report an error